The breakthrough of personalized medicine, new hopes and new challenges

Ronan Flippot, Christophe Massard, Edouard Auclin, David Azria, Héloïse Bourien, Philippe Rochigneux, Antoine Schernberg, Loïc Verlingue, Lara Zafrani, Stéphane Vignot

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)

    Abstract

    The development of personalized medicine in oncology is based on biomarkers that help select populations for more efficient and less toxic therapies. The onset of molecular biology led to new paradigms in drug development, with efficacy data reported in early clinical trials and accelerated approvals. Multiple clinical trials, including SHIVA, SAFIR-01 and MOSCATO-01, have been developed to evaluate the interest of treatment decision-making based on tumor molecular profiling, with the ambition to replace historical clinical and pathological classifications. Targeted molecular therapies have also drastically enhanced the prognosis of patients in several cancer subtypes, with increased use in the context of advanced palliative care. Breaking through those boundaries might lead to a true precision medicine in oncology, which implementation in clinical routine is now expected by patients and physicians.

    Translated title of the contributionQuelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie
    Original languageEnglish
    Pages (from-to)735-743
    Number of pages9
    JournalBulletin du Cancer
    Volume104
    Issue number9
    DOIs
    Publication statusPublished - 1 Sept 2017

    Keywords

    • Biomarker
    • Molecular targeted therapies
    • Personalized medicine

    Cite this